Multicenter characterization of enterocolitis associated with BCMA-directed CAR T cell therapy
Year: 2026
Type: article
Study design: Observational Study
Abstract: Immune effector cell-associated enterocolitis (IEC-EC) is a delayed toxicity of ciltacabtagene autoleucel. The US Multiple Myeloma Immunotherapy Consortium retrospectively adjudicated 54 suspected cases from 8 institutions: 41 were IEC-EC (31 confirmed by anti-camelid variable heavy-chain immunohistochemistry, 10 probable). Through September 2025, cumulative incidence was 3.0% (39 of 1,308 ciltacabtagene autoleucel recipients; 95% CI 2.1–4.1%); 12-month competing-risk incidence was 3.0% (95% CI 2.1–4.1%). Median symptom onset was 75 days after infusion. Grade ≥3 diarrhea occurred in 85% (34 of 40 with diarrhea); 73% (30 of 41) required parenteral nutrition. Despite normal upper endoscopy in 41% (9 of 22), duodenal biopsies showed villous blunting, apoptotic bodies and a dense cytotoxic T cell infiltrate, CD4 + in 61% (19 of 31), CD8 + in 26% (8 of 31) and mixed in 13% (4 of 31). A dominant T cell clone was detected in 76% (13 of 17 tested). Delayed neurotoxicity co-occurred in 41% (17 of 41). At last follow-up, 32% (13 of 41) resolved, 27% (11 of 41) had ongoing symptoms and 41% (17 of 41) died with active IEC-EC. Combined biologic and T cell-directed therapy yielded the highest resolution (55%, 6 of 11) in small subgroups. IEC-EC is potentially fatal and requires systematic evaluation and early directed therapy.
Source: Nature Medicine
Authors: Lekha Mikkilineni, Mark P. Hamilton, Alexandria Jensen, Kenneth JC Lim, Gliceida M. Galarza-Fortuna, Anupama D. Kumar, Christopher J. Ferreri, Andrew J. Portuguese, Hitomi Hosoya, Sharlene Dong, Nadine H. Abdallah, Jinming Song, Rebecca Gonzalez, Anna Shestakova, Navreet Chowla, Zongming Eric Chen, Amandeep Godara, Ghulam Rehman Mohyuddin, Max N. Brondfield, Dana Balitzer, Christopher J. Bowman, Omar Castaneda Puglianini, Michael G. Kattah, Frederick L. Locke, Louis S. Williams, Alaa Ali, Binod Dhakal, Rahul Banerjee, Metin Ozdemirli, David B. Miklos, Krina K. Patel, Douglas W. Sborov, Ajai Chari, Thomas Martin, Surbhi Sidana, Yi Lin, Francisco Vega, Sebastian Fernandez-Pol, Doris K. Hansen, David Y. Oh, Jeffrey L. Wolf
Institutions: Stanford Medicine, Stanford University, The University of Texas MD Anderson Cancer Center, Alfred Health, Monash University, University of Utah, Huntsman Cancer Institute, University of California, San Francisco, Levine Cancer Institute, Wake Forest University, Fred Hutch Cancer Center, Cedars-Sinai Medical Center, Mayo Clinic, Moffitt Cancer Center, ARUP Laboratories (United States), Cleveland Clinic, Medical College of Wisconsin, Georgetown University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $12,690
OpenAlex ID: W7236713982
